Design Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Operating income | -$79.5M | -$62.4M | -$78.2M | -$67.6M | -$35.8M |
| Operating expenses | $79.5M | $62.4M | $78.2M | $67.6M | $35.8M |
| Cash from operations | -$54.4M | -$43.1M | -$58.6M | -$51.3M | -$29.4M |
| Capital expenditure | $193,000 | $340,000 | $256,000 | $918,000 | $1.5M |
| Free cash flow | -$54.6M | -$43.4M | -$58.8M | -$52.2M | -$30.9M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $226.2M | $252.1M | $289.6M | $341.1M | $390.6M |
| Total liabilities | $13.7M | $10.0M | $12.0M | $13.8M | $8.4M |
Shares outstanding 62.5M · Free float 71.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.